Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 57, Issue 5, 2018, Pages 900-908

  Genovese, Mark C ^a   Kremer, Joel M ^b   Kartman, Cynthia E ^c   Schlichting, Douglas E ^c   Xie, Li ^c   Carmack, Tara ^c   Pantojas, Carlos ^d   Burson, Juan Sanchez ^e   Tony, Hans Peter ^f   Macias, William L ^c   Rooney, Terence P ^c   Smolen, Josef S ^g  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Latin Clinical Trial Center   (Puerto Rico)

^e Hospital Infanta Luisa   (Spain)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Baricitinib; Biologic disease modifying anti rheumatic drugs; Insufficient response; Janus kinase inhibitor; RA BEACON; Rheumatoid arthritis; Subgroup analysis; Tumor necrosis factor inhibitor

Indexed keywords

ABATACEPT; ADALIMUMAB; BARICITINIB; CANAKINUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOSTAMATINIB; INFLIXIMAB; INTERFERON; IXEKIZUMAB; METHOTREXATE; OCRELIZUMAB; OFATUMUMAB; OLOKIZUMAB; PLACEBO; RITUXIMAB; SARILUMAB; SECUKINUMAB; TABALUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; AZETIDINE DERIVATIVE; BIOLOGICAL PRODUCT; SULFONAMIDE;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CLINICAL DISEASE ACTIVITY INDEX; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; HUMAN; INFECTION; MIDDLE AGED; ODDS RATIO; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEROLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; FEMALE; FOLLOW UP; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ARTHRITIS, RHEUMATOID; AZETIDINES; BIOLOGICAL PRODUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85047763498     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex489     Document Type: Article

References (14)

1. Genovese MC, Kremer J, Zamani O et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243-52
2. SmolenJS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
3. Singh JA, Saag KG, Bridges SL Jr et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 2016;68:1-26
4. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 2015;11:276-89
5. Genovese MC, Schiff M, Luggen M et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-54
6. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
7. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23
8. Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21
9. Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60
10. Isaacs JD, Cohen SB, Emery P et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013;72:329-36
11. Alten R, Nü ßlein H, Galeazzi M et al. Baseline autoantibodies preferentially impact abatacept efficacy in patients with RA who are biologic naïve: 6-month results from a real-world, international, prospective study [abstract]. Arthritis Rheumatol 2015;67(Suppl 10):465
12. Schiff M, Kelly S, Le Bars M, Genovese M. Efficacy of abatacept in RA patients with an inadequate response to anti-TNF therapy regardless of reason for failure, or type or number of prior anti-TNF therapy used. Ann Rheum Dis 2008;67(Suppl 2):337
13. Kremer JM, Tony H, Tak PP, Luggen M, Mariette X, Hessey E. Efficacy of ritumixab in active RA patients with an inadequate response to one or more TNF inhibitors. Ann Rheum Dis 2006;65(Suppl 2):326
14. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70